<DOC>
	<DOCNO>NCT01845701</DOCNO>
	<brief_summary>To assess efficacy artesunate-amodiaquine , dihydroartemisinin-piperaquine , comparison artemether-lumefantrine 42 day follow period 720 child acute uncomplicated P. falciparum malaria , two different endemic ecological area - Savanna equatorial forest region Cameroon . We set specific objective : - To assess efficacy artesunate-amodiaquine , dihydroartemisinin-piperaquine , comparison artemether-lumefantrine 14 28 day follow period child acute uncomplicated P. falciparum malaria two different endemic area . - To evaluate safety artesunate-amodiaquine , dihydroartemisinin-piperaquine , comparison artemether-lumefantrine 42 day follow period child acute uncomplicated P. falciparum malaria . - To determine parasite clearance time ( PCT ) fever clearance time ( FCT ) follow administration three trial regimen . - To investigate treatment response base WHO criteria ( WHO , 2003 ) patient group trial . - To investigate Single Nucleotide Polymorphisms ( SNPs ) microsatellite marker gene associate drug resistance</brief_summary>
	<brief_title>Artemisinin-Based Antimalarial Combinations Clinical Response Cameroon</brief_title>
	<detailed_description>Methodology Children either gender , 6 month ( &gt; 5kg ) 10 year age , acute uncomplicated P. falciparum infection , fulfil inclusion none exclusion criterion enrol study . They randomise receive three trial arm , i.e , Study Arm-A : artesunate-amodiaquine , Study Arm-B : dihydroartemisinin-piperaquine Study Arm-C : artemether-lumefantrine ratio 2:2:1 hospitalise 3-day period facilitate supervise administration study drug full clinical laboratory assessment observation early adverse effect . On discharge , participant require report study clinic day 7 , 14 , 21,28 , 35 42 time clinical sign ( ) /symptom ( ) malaria suspect . The number participant 720 child Inclusion Criteria - Children either gender , age 6 month ( &gt; 5kg ) 10 year . - Suffering acute uncomplicated P. falciparum malaria confirm microscopy use Giemsa-stained thick film asexual parasite density 1,000 100,000 parasites/μl . - Presenting fever ( axillary temperature ≥ 37.5oC ) history fever precede 24 hour . - Able ingest tablet orally ( either suspend water uncrushed food ) . - Willing participate study write assent parent/guardian . Parental authorization obtain child less 8 year old document assent parents/guardians child 8-10 year . - Willing able attend clinic stipulate regular follow-up visit . Exclusion Criteria • Any follow `` danger sign severe malaria '' : Not able drink breast feed Persistent vomiting ( &gt; 2 episode within previous 24 hour ) Convulsions ( &gt; 1 episode within previous 24 hour ) Lethargic/unconscious - Signs/symptoms indicate severe/complicated malaria accord WHO criterion ( WHO definition ) . - Concomitant illness , underlie chronic hepatic renal disease , abnormal cardiac rhythm , hypoglycaemia , jaundice , respiratory distress , - Serious gastrointestinal disease , severe malnutrition ( W/H &lt; 70 % ) severe anaemia ( haemoglobin &lt; 5 g/dl ) . - Known hypersensitivity study drug .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Antimalarials</mesh_term>
	<mesh_term>Artemisinine</mesh_term>
	<criteria>Children either gender , age 6 month ( &gt; 5kg ) 10 year . Suffering acute uncomplicated P. falciparum malaria confirm microscopy use Giemsastained thick film asexual parasite density 1,000 100,000 parasites/μl . Presenting fever ( axillary temperature ≥ 37.5oC ) history fever precede 24 hour . Able ingest tablet orally ( either suspend water uncrushed food ) . Willing participate study write assent parent/guardian . Parental authorization obtain child less 8 year old document assent parents/guardians child 810 year . Willing able attend clinic stipulate regular followup visit . •Any follow `` danger sign severe malaria '' : Not able drink breast feed Persistent vomiting ( &gt; 2 episode within previous 24 hour ) Convulsions ( &gt; 1 episode within previous 24 hour ) Lethargic/unconscious Signs/symptoms indicate severe/complicated malaria accord WHO criterion ( WHO definition ) . Concomitant illness , underlie chronic hepatic renal disease , abnormal cardiac rhythm , hypoglycaemia , jaundice , respiratory distress , Serious gastrointestinal disease , severe malnutrition ( W/H &lt; 70 % ) severe anaemia ( haemoglobin &lt; 5 g/dl ) . Known hypersensitivity study drug .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>120 Months</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>malaria , cure rate , efficacy , safety</keyword>
</DOC>